{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T22:50:00Z","timestamp":1773010200229,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.lfs.2020.118261","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T01:22:13Z","timestamp":1597195333000},"page":"118261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK\/STAT and TLR-4\/NF-\u03baB signaling pathways"],"prefix":"10.1016","volume":"260","author":[{"given":"Sherihan Salaheldin Abdelhamid","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona Abdelrazek","family":"Salama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Selima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rowaida Refaat","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.lfs.2020.118261_bb0005","first-page":"19","article-title":"Pathogenesis of rheumatoid arthritis","volume":"61","author":"Branimir","year":"2014","journal-title":"Reumatizam"},{"issue":"Suppl. 5","key":"10.1016\/j.lfs.2020.118261_bb0010","doi-asserted-by":"crossref","first-page":"v3","DOI":"10.1093\/rheumatology\/kes113","article-title":"Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis","volume":"51","author":"Choy","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.lfs.2020.118261_bb0015","doi-asserted-by":"crossref","first-page":"822","DOI":"10.4161\/hv.27910","article-title":"Emerging immunotherapies for rheumatoid arthritis","volume":"10","author":"Reynolds","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"issue":"Supplement_1","key":"10.1016\/j.lfs.2020.118261_bb0020","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.lfs.2020.118261_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20140712","article-title":"The molecular regulation of Janus kinase (JAK) activation","volume":"462","author":"Babon","year":"2014","journal-title":"Biochem. J."},{"key":"10.1016\/j.lfs.2020.118261_bb0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13075-015-0638-x","article-title":"Associations of antibodies against citrullinated peptides with human leukocyte antigen-shared epitope and smoking prior to the development of rheumatoid arthritis","volume":"17","author":"Kokkonen","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.lfs.2020.118261_bb0035","series-title":"Arthritis and Allied Conditions","first-page":"1089","article-title":"Etiology and pathogenesis of rheumatoid arthritis","author":"Fox","year":"2004"},{"issue":"3","key":"10.1016\/j.lfs.2020.118261_bb0040","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/BOR.0b013e32835fb8ec","article-title":"Periodontal disease and rheumatoid arthritis: the evidence accumulates for complex pathobiologic interactions","volume":"25","author":"Bingham","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.lfs.2020.118261_bb0045","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2147\/DDDT.S109287","article-title":"Sitagliptin attenuates cardiomyopathy by modulating the JAK\/STAT signaling pathway in experimental diabetic rats","volume":"10","author":"Al-Rasheed","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"issue":"3","key":"10.1016\/j.lfs.2020.118261_bb0050","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0092-8674(00)81109-5","article-title":"Rheumatoid arthritis","volume":"85","author":"Feldmann","year":"1996","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.lfs.2020.118261_bb0055","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.lfs.2020.118261_bb0060","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40265-013-0065-8","article-title":"Tofacitinib: a review of its use in adult patients with rheumatoid arthritis","volume":"73","author":"Scott","year":"2013","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.lfs.2020.118261_bb0065","doi-asserted-by":"crossref","first-page":"503","DOI":"10.4103\/idoj.IDOJ_474_18","article-title":"Oral tofacitinib: contemporary appraisal of its role in dermatology","volume":"10","author":"Sonthalia","year":"2019","journal-title":"Indian Dermatol. Online J."},{"key":"10.1016\/j.lfs.2020.118261_bb0070","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejphar.2012.10.024","article-title":"Evaluation of the effect of losartan and methotrexate combined therapy in adjuvant induced arthritis in rats","volume":"698","author":"Refaat","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.lfs.2020.118261_bb0075","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1002\/art.34649","article-title":"JAK inhibition with tofacitinib suppresses arthritc joint structural damage through decreased RANKL production","volume":"64","author":"LaBranche","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.lfs.2020.118261_bb0080","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/1529-0131(199808)41:8<1407::AID-ART9>3.0.CO;2-H","article-title":"The effect of methotrexate and 7-hydroxymethotrexate on rat adjuvant arthritis and on urinary aminoimidazole carboxamide excretion","volume":"41","author":"Baggott","year":"1998","journal-title":"Arthritis Rheum."},{"issue":"1\u20133","key":"10.1016\/j.lfs.2020.118261_bb0085","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ejphar.2013.07.002","article-title":"The combined effect of metformin and L-cysteine on inflammation, oxidative stress and insulin resistance in streptozotocin-induced type 2 diabetes in rats","volume":"714","author":"Salman","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118261_bb0090","first-page":"32","article-title":"Estimation of the concentrations of low-density lipoprotein - an integral approach to mechanisms and disorders","volume":"276","author":"Friedwald","year":"1967","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lfs.2020.118261_bb0095","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/ajcp\/28.1.56","article-title":"A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases","volume":"28","author":"Reitman","year":"1957","journal-title":"Am. J. Clin. Pathol."},{"issue":"2","key":"10.1016\/j.lfs.2020.118261_bb0100","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0009-8981(72)90146-5","article-title":"Creatinine assay in the presence of protein with LKB 8600 reaction rate analyser","volume":"38","author":"Larsen","year":"1972","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.lfs.2020.118261_bb0105","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/clinchem\/9.1.102","article-title":"A new simple semimicro method for colorimetric determination of urea","volume":"9","author":"Coulombe","year":"1963","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.lfs.2020.118261_bb0110","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ejphar.2005.05.005","article-title":"Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis","volume":"516","author":"Barsante","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118261_bb0115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2105-7-85","article-title":"Statistical analysis of real-time PCR data","volume":"7","author":"Yuan","year":"2006","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.lfs.2020.118261_bb0120","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejphar.2004.12.014","article-title":"Prevention of progressive joint destruction in adjuvant induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR217840","volume":"508","author":"Ishikawa","year":"2005","journal-title":"Eur. J. Pharmacol."},{"issue":"15","key":"10.1016\/j.lfs.2020.118261_bb0125","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2169\/internalmedicine.51.7592","article-title":"Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report","volume":"51","author":"Yokota","year":"2012","journal-title":"Intern. Med."},{"key":"10.1016\/j.lfs.2020.118261_bb0130","doi-asserted-by":"crossref","first-page":"7965317","DOI":"10.1155\/2016\/7965317","article-title":"Analysis of inflammatory mediators in prediabetes and newly diagnosed type 2 diabetes patients","volume":"2016","author":"Wang","year":"2016","journal-title":"J. Diabetes Res."},{"issue":"9","key":"10.1016\/j.lfs.2020.118261_bb0135","article-title":"Anti-Inflammatory, anti-arthritic and anti-nociceptive activities of Nigella sativa oil in a rat model of arthritis","volume":"8","author":"Nasuti","year":"2019","journal-title":"Antioxidants (Basel)"},{"issue":"3","key":"10.1016\/j.lfs.2020.118261_bb0140","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/BOR.0b013e3283369cb8","article-title":"B cells in the pathogenesis and treatment of rheumatoid arthritis","volume":"22","author":"Marston","year":"2010","journal-title":"Curr. Opin. Rheumatol."},{"issue":"1","key":"10.1016\/j.lfs.2020.118261_bb0145","first-page":"26","article-title":"Effect of sitagliptin and methotrexate on rheumatoid arthritis induced experimentally in rats","volume":"7","author":"Abdel-Aziz","year":"2017","journal-title":"Egypt. J. Basic Clin. Pharmacol."},{"issue":"23","key":"10.1016\/j.lfs.2020.118261_bb0150","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.2174\/092986709788803114","article-title":"Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme","volume":"16","author":"Matteucci","year":"2009","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.lfs.2020.118261_bb0155","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/s10165-012-0799-2","article-title":"JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical","volume":"23","author":"Tanaka","year":"2013","journal-title":"Mod. Rheumatol."},{"issue":"Suppl. 2","key":"10.1016\/j.lfs.2020.118261_bb0160","doi-asserted-by":"crossref","first-page":"i70","DOI":"10.1136\/annrheumdis-2011-200595","article-title":"In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis","volume":"71","author":"Tanaka","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.lfs.2020.118261_bb0165","first-page":"571","article-title":"The interplay between monocytes\/macrophages and CD4 (+) T cell subsets in rheumatoid arthritis","volume":"19","author":"Roberts","year":"2015","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.lfs.2020.118261_bb0170","doi-asserted-by":"crossref","first-page":"e0178879","DOI":"10.1371\/journal.pone.0178879","article-title":"Level of inflammatory cytokines in rheumatoid arthritis patients: correlation with 25-hydroxy vitamin D and reactive oxygen species","volume":"12","author":"Mateen","year":"2017","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.lfs.2020.118261_bb0175","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/intimm\/dxr077","article-title":"IL1beta and TNFalpha-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis","volume":"23","author":"Mori","year":"2011","journal-title":"Int. Immunol."},{"issue":"3","key":"10.1016\/j.lfs.2020.118261_bb0180","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/aps.2012.187","article-title":"Norisoboldine alleviates joint destruction in rats with adjuvant-induced arthritis by reducing RANKL, IL-6, PGE (2), and MMP-13 expression","volume":"34","author":"Wei","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.lfs.2020.118261_bb0185","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3389\/fphar.2017.00407","article-title":"Sitagliptin, an anti-diabetic drug, suppresses estrogen deficiency-induced osteoporosis in vivo and inhibits RANKL-induced osteoclast formation and bone resorption in vitro","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.lfs.2020.118261_bb0190","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2020.118261_bb0195","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/rheumatology\/ken363","article-title":"IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-\u03b1 and IL-17","volume":"47","author":"Hashizume","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lfs.2020.118261_bb0200","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","article-title":"Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors","volume":"75","author":"Gao","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.lfs.2020.118261_bb0205","doi-asserted-by":"crossref","first-page":"45006","DOI":"10.1038\/srep45006","article-title":"Resveratrol mitigates lipopolysaccharide-mediated acute inflammation in rats by inhibiting the TLR4\/NF-\u03baBp65\/MAPKs signaling cascade","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2020.118261_bb0210","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3389\/fimmu.2019.00705","article-title":"NF-\u03baB signaling in macrophages: dynamics, crosstalk, and signal integration","volume":"10","author":"Dorrington","year":"2019","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.lfs.2020.118261_bb0215","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/jat.1342","article-title":"Effect of inflammation on kidney function and pharmacokinetics of COX-2 selective nonsteroidal anti-inflammatory drugs rofecoxib and meloxicam","volume":"28","author":"Harirforoosh","year":"2008","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.lfs.2020.118261_bb0220","doi-asserted-by":"crossref","first-page":"9670434","DOI":"10.1155\/2017\/9670434","article-title":"Abnormal glucose metabolism in rheumatoid arthritis","volume":"2017","author":"Pi","year":"2017","journal-title":"Biomed. Res. Int."},{"issue":"11","key":"10.1016\/j.lfs.2020.118261_bb0225","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3109\/13880209.2014.1001404","article-title":"Hematological and lipid profile evaluation of a hexanefraction of Costus afer leaves in arthritic rats","volume":"53","author":"Anyasor","year":"2015","journal-title":"Pharm. Biol."},{"issue":"18","key":"10.1016\/j.lfs.2020.118261_bb0230","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/bph.13932","article-title":"Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis","volume":"174","author":"P\u00e9rez-Baos","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.lfs.2020.118261_bb0235","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jbspin.2016.09.001","article-title":"Rheumatoid arthritis, insulin resistance, and diabetes","volume":"84","author":"Nicolau","year":"2017","journal-title":"Joint Bone Spine"},{"issue":"9","key":"10.1016\/j.lfs.2020.118261_bb0240","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1210\/jc.2012-1544","article-title":"Sitagliptin exerts an antinflammatory action","volume":"97","author":"Makdissi","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.lfs.2020.118261_bb0245","doi-asserted-by":"crossref","first-page":"e0174295","DOI":"10.1371\/journal.pone.0174295","article-title":"Hepatoprotective effect of sitagliptin against methotrexate induced liver toxicity","volume":"12","author":"Abo-Haded","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2020.118261_bb0250","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/j.1476-5381.2012.01836.x","article-title":"Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study","volume":"166","author":"Balagu\u00e9","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.lfs.2020.118261_bb0255","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrrheum.2013.91","article-title":"Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm","volume":"9","author":"Robertson","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.lfs.2020.118261_bb0260","doi-asserted-by":"crossref","first-page":"162092","DOI":"10.1155\/2011\/162092","article-title":"Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (zucker diabetic fatty rat)","volume":"2011","author":"Mega","year":"2011","journal-title":"Exp. Diabetes Res."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520310134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520310134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T10:22:40Z","timestamp":1717237360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320520310134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":52,"alternative-id":["S0024320520310134"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2020.118261","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK\/STAT and TLR-4\/NF-\u03baB signaling pathways","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2020.118261","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"118261"}}